Bup was well tolerated in patients with PI3K-activated recurrent glioblastoma but exhibited minimal efficacy as single agent. In spite of significant brain penetration, it lacked clinical efficacy due to the inability to block the PI3K pathway when evaluated in tumor tissues. Here, PIK3CA is linked to glioblastoma.